Showing results (1-10 of 351) with videos related to

Sort By:
Pageof 36
Biomedicines|December 30, 2025
Variation in Pathological Appearance Across Repeated Sampling from Probably Benign Breast LesionsAthanasios Zouzos, Irma Fredriksson, Theodoros Foukakis, et al.
European Journal of Radiology|March 24, 2025
Patient experience and healthcare cost aspects of vacuum-assisted excision of breast lesions. A report from the Swedish VAE randomized clinical trialAthanasios Zouzos, Irma Fredriksson, Andreas Karakatsanis, et al.
European Journal of Radiology|December 26, 2024
Effect of needle size on outcomes of vacuum-assisted excision of breast lesions. A randomized controlled trialAthanasios Zouzos, Irma Fredriksson, Andreas Karakatsanis, et al.
JMIR AI|June 14, 2024
Effect of Benign Biopsy Findings on an Artificial Intelligence-Based Cancer Detector in Screening Mammography: Retrospective Case-Control StudyAthanasios Zouzos, Aleksandra Milovanovic, Karin Dembrower, et al.
Nature Medicine|July 8, 2024
AI-based selection of individuals for supplemental MRI in population-based breast cancer screening: the randomized ScreenTrustMRI trialMattie Salim, Yue Liu, Moein Sorkhei, et al.
Breast Cancer Research and Treatment|September 19, 2018
Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registryClaudette Falato, Sara K Taylor, Robert Szulkin, et al.
Breast Cancer Research : BCR|February 6, 2024
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancerCaroline Rönnlund, Emmanouil G Sifakis, Caroline Schagerholm, et al.
Histopathology|December 11, 2013
Low concordance of biomarkers in histopathological and cytological material from breast cancerGustav Stålhammar, Gustaf Rosin, Irma Fredriksson, et al.
Breast (Edinburgh, Scotland)|June 13, 2026
A nationwide population-based study on the incidence and prognosis of HER2-positive breast cancer eligible for adjuvant pertuzumab in the modern era of neoadjuvant therapyAntonis Valachis, Xingrong Liu, Balazs Acs, et al.
The Lancet Regional Health. Europe|May 15, 2024
Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort studyBalazs Acs, Johan Hartman, Demet Sönmez, et al.
Pageof 36